Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
Sara A Hurvitz, Reva KakkarDepartment of Medicine, University of California, Los Angeles, CA, USAPurpose: This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth fac...
Guardado en:
Autores principales: | Hurvitz SA, Kakkar R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/87e80cf377974dfe9bec9c5365afb926 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
por: Merriam PA, et al.
Publicado: (2011) -
Role of pertuzumab in the treatment of HER2-positive breast cancer
por: Hubalek M, et al.
Publicado: (2012) -
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra DR, et al.
Publicado: (2014) -
The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno I, et al.
Publicado: (2015) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015)